Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) has been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $6.92.
A number of research analysts have recently commented on CDLX shares. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a report on Friday, January 17th. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th.
Cardlytics Stock Up 5.2 %
Insider Activity
In other Cardlytics news, CEO Amit Gupta sold 46,857 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total transaction of $159,313.80. Following the completion of the sale, the chief executive officer now owns 418,637 shares of the company’s stock, valued at approximately $1,423,365.80. This represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alexis Desieno sold 8,854 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the sale, the chief financial officer now directly owns 121,976 shares of the company’s stock, valued at $447,651.92. This represents a 6.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 111,454 shares of company stock valued at $391,864 over the last quarter. 4.40% of the stock is owned by company insiders.
Institutional Trading of Cardlytics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDLX. SG Americas Securities LLC acquired a new stake in Cardlytics during the 3rd quarter valued at approximately $45,000. Creative Planning increased its position in Cardlytics by 35.4% during the 3rd quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after purchasing an additional 7,721 shares during the period. Acorn Financial Advisory Services Inc. ADV increased its position in Cardlytics by 40.5% during the 3rd quarter. Acorn Financial Advisory Services Inc. ADV now owns 164,409 shares of the company’s stock valued at $526,000 after purchasing an additional 47,358 shares during the period. GSA Capital Partners LLP increased its position in Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares during the period. Finally, Brooktree Capital Management increased its position in Cardlytics by 24.7% during the 3rd quarter. Brooktree Capital Management now owns 167,642 shares of the company’s stock valued at $536,000 after purchasing an additional 33,169 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Recommended Stories
- Five stocks we like better than Cardlytics
- 3 Stocks to Consider Buying in October
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Short Selling – The Pros and Cons
- 5 Best Gold ETFs for March to Curb Recession Fears
- Growth Stocks: What They Are, What They Are Not
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.